Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
A next-generation Novo Nordisk metabolic disorder drug led to statistically significant weight loss in a pivotal test in participants with obesity and type 2 diabetes, results it says support ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
STORY: Shares of Novo Nordisk tumbled 10% Monday morning after the drugmaker revealed weaker-than-expected data about its latest obesity drug candidate, CagriSema. Investors were hoping a second ...
AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.
Proficio Capital Partners LLC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in the 4th quarter, ...
Meanwhile, Novo Nordisk's stock was hit ... a note to clients Wednesday that the deal adds to Roche's efforts in the obesity space and that the next-gen amylin space is likely to heat up.
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback